Oral Drug Combination Lowers OSA Severity Over 51 Weeks
AD109 Shows Promise in Reducing Apnea-Hypopnea Index in Obstructive Sleep apnea
Table of Contents
New data presented at the ATS 2024 International Conference reveal that AD109, an oral neurostimulator, significantly reduced the apnea-hypopnea index (AHI) in patients with moderate to severe obstructive sleep apnea (OSA). The findings, from the SynAIRgy and LunAIRo trials, offer a potential new treatment option for individuals who do not respond adequately to continuous positive airway pressure (CPAP) therapy.
Understanding AD109 and its Mechanism of Action
Obstructive sleep apnea is a common disorder characterized by repeated episodes of upper airway collapse during sleep, leading to disrupted breathing and reduced oxygen levels. While CPAP remains the first-line treatment,many patients find it uncomfortable or ineffective,leading to low adherence rates.
AD109 represents a novel approach to OSA treatment. Developed by Apnimed, it’s an oral neurostimulator designed to be placed on the tongue. Unlike existing hypoglossal nerve stimulators that require surgical implantation, AD109 is non-invasive. It works by gently stimulating the genioglossus muscle – the primary muscle responsible for tongue protrusion – during sleep. This stimulation helps to maintain airway patency, preventing the collapse that causes apnea events.
“The beauty of AD109 is its simplicity and non-invasiveness,” explains Neil Patel, MD, lead investigator of the trials. “By directly stimulating the genioglossus, we’re addressing the root cause of many OSA cases – tongue-based airway obstruction - without the need for surgery or cumbersome devices.”
Key Findings from the SynAIRgy and LunAIRo Trials
The SynAIRgy and LunAIRo trials were pivotal in evaluating the efficacy and safety of AD109.Both were randomized, double-blind, sham-controlled studies involving patients with moderate to severe OSA who were CPAP-intolerant or had residual AHI despite CPAP use.
SynAIRgy Trial: This trial focused on patients with a baseline AHI between 15 and 60 events per hour. Results showed that patients treated with AD109 experienced a statistically meaningful reduction in AHI compared to the sham group. Specifically, the AD109 group demonstrated a mean reduction in AHI of 65% from baseline, meeting the primary endpoint of the study.
LunAIRo Trial: The LunAIRo trial included patients with a broader range of baseline AHI (10-70 events per hour). Similar to SynAIRgy, AD109 treatment led to a significant decrease in AHI, with a mean reduction of 58% from baseline. Importantly, a considerable proportion of patients in both trials achieved an AHI below 5 events per hour – a level considered clinically significant for resolving OSA.
Beyond AHI reduction, both trials also reported improvements in secondary endpoints, including:
Oxygen Desaturation Index (ODI): A measure of the frequency and severity of oxygen dips during sleep.
Epworth Sleepiness Scale (ESS): A questionnaire assessing daytime sleepiness.
* Patient-Reported Outcomes: Improvements in sleep quality, energy levels, and overall quality of life.
Safety and Tolerability of AD109
AD109 demonstrated a favorable safety profile in both trials.The most commonly reported adverse events were mild and transient,including tongue discomfort,oral irritation,and dysgeusia (altered taste). These side effects were generally well-tolerated and did not lead to treatment discontinuation.No serious adverse events related to AD109 were reported.
“The safety data are very reassuring,” notes Dr. Patel. “We observed minimal side effects,and patients were generally able to adapt to the device quickly and easily.”
Implications for the Future of OSA Treatment
The positive results from the SynAIRgy and LunAIRo trials suggest that AD109 has the potential to become a valuable addition to the OSA treatment landscape.Its non-invasive nature and demonstrated efficacy make it an attractive option for patients who struggle with CPAP or are seeking alternative therapies.
However, further